Scholars@Duke
James Enlou Tcheng

James Enlou Tcheng

Professor of Medicine
Medicine, Cardiology
tchen001@mc.duke.edu
Duke Box 2708, Durham, NC 27710
Suite 403 Hock Plaza, 2424 Erwin Road, Durham, NC
Office hours Normal business hours.  

Selected Publications

Translating proof-of-concept for platelet slip into improved antithrombotic therapeutic regimens.

Journal Article Platelets · December 2024 Platelets are central to thrombosis. Research at the intersection of biological and physical sciences provides proof-of-concept for shear rate-dependent platelet slip at vascular stenosis and near device surfaces. Platelet slip extends the observed biologi ... Full text Link to item Cite

The high price of equity in pulse oximetry: A cost evaluation and need for interim solutions.

Journal Article PLOS Digit Health · September 2024 Disparities in pulse oximetry accuracy, disproportionately affecting patients of color, have been associated with serious clinical outcomes. Although many have called for pulse oximetry hardware replacement, the cost associated with this replacement is not ... Full text Link to item Cite

Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force.

Journal Article Value Health · June 2024 This ISPOR Good Practices report provides a framework for assessing the suitability of electronic health records data for use in health technology assessments (HTAs). Although electronic health record (EHR) data can fill evidence gaps and improve decisions ... Full text Link to item Cite

Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways "LEAN" working group.

Journal Article J Vasc Surg · November 2023 Registry Assessment of Peripheral Interventional Devices (RAPID) initiated the Pathways Program to provide a transparent, collaborative forum in which to pursue insights into multiple unresolved questions on benefit-risk of paclitaxel-coated devices, inclu ... Full text Link to item Cite

Artificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions.

Journal Article JACC Cardiovasc Interv · October 23, 2023 Artificial intelligence, computational simulations, and extended reality, among other 21st century computational technologies, are changing the health care system. To collectively highlight the most recent advances and benefits of artificial intelligence, ... Full text Link to item Cite

Optimizing strategies for clinical decision support: Summary of a meeting series

Book · September 8, 2023 As a result of a collaboration between the National Academy of Medicine (NAM) and the Office of the National Coordinator for Health Information Technology, this NAM Special Publication summarizes and builds on a meeting series in which a multi-stakeholder ... Full text Cite

Data and databases in cardiovascular medicine and surgery

Chapter · January 1, 2023 Vast amounts of complex information are created in the processes of healthcare. This chapter delineates three categories of computational readiness of that information: native data that is analytics (and AI) ready, discrete data that must be translated to ... Full text Cite

Multi-institutional distributed data networks for real-world evidence about medical devices: building unique device identifiers into longitudinal data (BUILD).

Journal Article JAMIA Open · July 2022 OBJECTIVES: To support development of a robust postmarket device evaluation system using real-world data (RWD) from electronic health records (EHRs) and other sources, employing unique device identifiers (UDIs) to link to device information. METHODS: To cr ... Full text Link to item Cite

Systematic review of current natural language processing methods and applications in cardiology.

Journal Article Heart · May 25, 2022 Natural language processing (NLP) is a set of automated methods to organise and evaluate the information contained in unstructured clinical notes, which are a rich source of real-world data from clinical care that may be used to improve outcomes and unders ... Full text Link to item Cite

ACGME Interventional Cardiology Milestones 2.0-an overview: Endorsed by the Accreditation Council for Graduate Medical Education.

Journal Article Catheter Cardiovasc Interv · February 2022 This document provides an overview of the rationale, development, interpretation, and practical suggestions for implementation of the new Accreditation Council for Graduate Medical Education (ACGME) Interventional Cardiology (IC) Milestones 2.0. Previously ... Full text Link to item Cite

Advancing Patient Safety Surrounding Medical Devices: Barriers, Strategies, and Next Steps in Health System Implementation of Unique Device Identifiers.

Journal Article Med Devices (Auckl) · 2022 BACKGROUND: The requirement for medical device manufacturers to label their devices with a unique device identifier (UDI) was formalized by the 2013 US Food and Drug Administration Unique Device Identification System Rule. However, parallel regulatory requ ... Full text Link to item Cite

Developing minimum core data structure for the obesity devices Coordinated Registry Network (CRN).

Journal Article BMJ Surg Interv Health Technol · 2022 Obesity continues to be a major public health issue, with more than two-thirds of adults in the USA categorized as overweight or obese. Bariatric surgery is effective and yields durable weight loss; however, few qualified candidates choose to undergo surgi ... Full text Open Access Link to item Cite

Advancing the Real-World Evidence for Medical Devices through Coordinated Registry Networks.

Journal Article BMJ Surg Interv Health Technol · 2022 OBJECTIVES: Generating and using real-world evidence (RWE) is a pragmatic solution for evaluating health technologies. RWE is recognized by regulators, health technology assessors, clinicians, and manufacturers as a valid source of information to support t ... Full text Link to item Cite

Roadmap to a more useful and usable electronic health record.

Journal Article Cardiovasc Digit Health J · December 2021 BACKGROUND: A decade after the Health Information Technology for Economic and Clinical Health (HITECH) Act, electronic health records (EHRs) largely remain poorly designed and contribute to clinician burnout. OBJECTIVE: The purpose of this study was to und ... Full text Link to item Cite

Multispecialty Enterprise Imaging Workgroup Consensus on Interactive Multimedia Reporting Current State and Road to the Future: HIMSS-SIIM Collaborative White Paper.

Journal Article J Digit Imaging · June 2021 Diagnostic and evidential static image, video clip, and sound multimedia are captured during routine clinical care in cardiology, dermatology, ophthalmology, pathology, physiatry, radiation oncology, radiology, endoscopic procedural specialties, and other ... Full text Link to item Cite

Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions.

Journal Article J Vasc Surg · May 2021 BACKGROUND: The Superficial Femoral Artery-Popliteal EvidencE Development Study Group developed contemporary objective performance goals (OPGs) for peripheral vascular interventions (PVI) for superficial femoral artery (SFA)-popliteal artery disease using ... Full text Link to item Cite

Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative.

Journal Article Ther Innov Regul Sci · January 2021 BACKGROUND: Patient registries are organized systems that use observational methods to collect uniform data on specified outcomes in a population defined by a particular disease, condition, or exposure. Data collected in registries often coincide with data ... Full text Link to item Cite

Advancing Patient Safety Surrounding Medical Devices: A Health System Roadmap to Implement Unique Device Identification at the Point of Care.

Journal Article Med Devices (Auckl) · 2021 BACKGROUND: The US Food and Drug Administration's Unique Device Identification System Rule of 2013 mandated manufacturers to assign unique device identifiers (UDIs) to their medical devices. Most high-risk (Class III), moderate-risk (Class II) and implanta ... Full text Link to item Cite

The Medical Device Unique Device Identifier as the Single Source of Truth in Healthcare Enterprises - Roadmap for Implementation of the Clinically Integrated Supply Chain.

Journal Article Med Devices (Auckl) · 2021 Documentation and tracking of supplies, equipment and medical devices is central to operational, financial, and clinical aspects of safe, efficient, and effective patient care. The labeling of medical devices with a unique device identifier (UDI) creates t ... Full text Link to item Cite

SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention.

Journal Article J Cardiovasc Pharmacol · August 2020 OBJECTIVE: The natural molecule α-lipoic acid has been shown to be partially cytoprotective through antioxidant and antiapoptotic mechanisms. To obtain an initial assessment of the safety and potential efficacy of a synthetic derivative, CMX-2043, in preve ... Full text Link to item Cite

Telehealth transformation: COVID-19 and the rise of virtual care.

Journal Article J Am Med Inform Assoc · June 1, 2020 The novel coronavirus disease-19 (COVID-19) pandemic has altered our economy, society, and healthcare system. While this crisis has presented the U.S. healthcare delivery system with unprecedented challenges, the pandemic has catalyzed rapid adoption of te ... Full text Open Access Link to item Cite

Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry.

Journal Article Am Heart J · September 2019 BACKGROUND: Hybrid revascularization, combining percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), may be used differently across hospitals. How outcomes compare with multivessel PCI is unknown. METHODS: We studied hybrid ... Full text Link to item Cite

Artificial Intelligence and Machine Learning in Cardiology.

Journal Article JACC Cardiovasc Interv · July 22, 2019 Full text Link to item Cite

Achieving Data Liquidity: Lessons Learned from Analysis of 38 Clinical Registries (The Duke-Pew Data Interoperability Project.

Journal Article AMIA Annu Symp Proc · 2019 BACKGROUND: To assess the current state of clinical data interoperability, we evaluated the use of data standards across 38 large professional society registries. METHODS: The analysis included 4 primary components: 1) environmental scan, 2) abstraction an ... Open Access Link to item Cite

Primary Angioplasty A Practical Guide

Book · July 13, 2018 The book is also relevant for healthcare providers and emergency department physicians. This book is open access under a CC BY 4.0 license. ... Cite

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Journal Article J Am Coll Cardiol · March 6, 2018 This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the U.S. Food and Drug Administration (FDA). The FDA established the Standardized D ... Full text Link to item Cite

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Journal Article Circulation · February 27, 2018 This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US Food and Drug Administration (FDA). The FDA established the Standardized Dat ... Full text Link to item Cite

Constructing the informatics and information technology foundations of a medical device evaluation system: a report from the FDA unique device identifier demonstration.

Journal Article J Am Med Inform Assoc · February 1, 2018 OBJECTIVE: The US Food and Drug Administration (FDA) has recognized the need to improve the tracking of medical device safety and performance, with implementation of Unique Device Identifiers (UDIs) in electronic health information as a key strategy. The F ... Full text Link to item Cite

Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements.

Journal Article J Vasc Surg · February 2018 OBJECTIVE: The current state of evaluating patients with peripheral artery disease and more specifically of evaluating medical devices used for peripheral vascular intervention (PVI) remains challenging because of the heterogeneity of the disease process, ... Full text Link to item Cite

Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory.

Journal Article J Am Coll Cardiol · January 30, 2018 The current heart failure clinical trial environment is strained by increasing complexity and cost, regulatory requirements, competing demands on stakeholders, implementation challenges, and decreasing patient and investigator participation. To begin the p ... Full text Link to item Cite

Registry Assessment of Peripheral Interventional Devices (RAPID)　- Registry Assessment of Peripheral Interventional Devices Core Data Elements.

Journal Article Circ J · January 25, 2018 BACKGROUND: The current state of evaluating patients with peripheral artery disease and more specifically of evaluating medical devices used for peripheral vascular intervention (PVI) remains challenging because of the heterogeneity of the disease process, ... Full text Link to item Cite

Advancing medical device innovation through collaboration and coordination of structured data capture pilots: Report from the Medical Device Epidemiology Network (MDEpiNet) Specific, Measurable, Achievable, Results-Oriented, Time Bound (SMART) Think Tank.

Journal Article Healthc (Amst) · December 2017 The Medical Device Epidemiology Network (MDEpiNet) is a public private partnership (PPP) that provides a platform for collaboration on medical device evaluation and depth of expertise for supporting pilots to capture, exchange and use device information fo ... Full text Link to item Cite

RESPONSE: Enabling the Learning Health System, One FIT at a Time

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · November 1, 2017 Link to item Cite

Primary PCI in ST-elevation myocardial infarction

Chapter · September 11, 2017 This chapter specifically focuses on the role of the cardiac catheterization laboratory in stent thrombosis elevation myocardial infarction (STEMI). A comprehensive knowledge of STEMI and percutaneous coronary intervention (PCI) guidelines, as well as an u ... Full text Cite

Morbidity and Mortality Conference for Percutaneous Coronary Intervention.

Journal Article Circ Cardiovasc Qual Outcomes · August 2017 BACKGROUND: Morbidity and mortality conference is a common educational and quality improvement activity performed in cardiac catheterization laboratories, but best practices for case selection and for maximizing the effectiveness of peer review have not be ... Full text Link to item Cite

The Learning Healthcare System and Cardiovascular Care: A Scientific Statement From the American Heart Association.

Journal Article Circulation · April 4, 2017 The learning healthcare system uses health information technology and the health data infrastructure to apply scientific evidence at the point of clinical care while simultaneously collecting insights from that care to promote innovation in optimal healthc ... Full text Link to item Cite

Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry.

Journal Article Coron Artery Dis · September 2016 OBJECTIVES: We sought to examine trends in use and outcomes of second-generation drug-eluting stents (DES) across sexes in a contemporary percutaneous coronary intervention (PCI) cohort. BACKGROUND: Sparse female enrollment in trials comparing first-genera ... Full text Link to item Cite

Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.

Journal Article Circ Heart Fail · July 2016 BACKGROUND: Contrast media administered during cardiac catheterization can affect hemodynamic variables. However, little is documented about the effects of contrast on hemodynamics in heart failure patients or the prognostic value of baseline and changes i ... Full text Link to item Cite

Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.

Journal Article Circ Cardiovasc Genet · April 2016 The process of scientific discovery is rapidly evolving. The funding climate has influenced a favorable shift in scientific discovery toward the use of existing resources such as the electronic health record. The electronic health record enables long-term ... Full text Link to item Cite

Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet).

Journal Article Am Heart J · January 2016 The MDEpiNet is a public-private partnership between the US Food and Drug Administration's Center for Devices and Radiological Health and participating partners. The PASSION program is an MDEpiNet-sponsored program that aims to demonstrate the goals of MDE ... Full text Link to item Cite

Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention.

Journal Article J Am Heart Assoc · July 6, 2015 BACKGROUND: Cardiovascular disease and cancer increasingly coexist, yet relationships between cancer and long-term cardiovascular outcomes post-percutaneous coronary intervention (PCI) are not well studied. METHODS AND RESULTS: We examined stented PCI pati ... Full text Open Access Link to item Cite

Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms.

Journal Article Ther Innov Regul Sci · July 2015 Detection of off-target cardiovascular (CV) effects remains a significant challenge to drug development. Documentation of CV events in non-CV trials is often inadequate to interpret imbalances between treatment arms, which may lead to concerns about potent ... Full text Link to item Cite

Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC).

Journal Article J Am Coll Cardiol · March 10, 2015 The lack of consistent definitions and nomenclature across clinical trials of novel devices, drugs, or biologics poses a significant barrier to accrual of knowledge in and across peripheral artery disease therapies and technologies. Recognizing this proble ... Full text Link to item Cite

Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration.

Journal Article Am Heart J · October 2014 BACKGROUND: Although electronic product identification in the consumer sector is ubiquitous, unique identification of medical devices is just being implemented in 2014. To evaluate unique device identifiers (UDIs) in health care, the US Food and Drug Admin ... Full text Link to item Cite

Detailed analysis of polymer response to delivery balloon expansion of drug-eluting stents versus bare metal stents.

Journal Article EuroIntervention · July 2013 AIMS: We sought to describe the response of the polymer surface of drug-eluting stents (DES) to delivery balloon expansion, including quantitation of any resulting detached microparticles. METHODS AND RESULTS: We expanded the US Food and Drug Administratio ... Full text Link to item Cite

Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery.

Journal Article Am Heart J · June 2013 BACKGROUND: In patients with acute ST-elevation myocardial infarction (STEMI) needing early coronary artery bypass graft (CABG) surgery, it is unknown whether primary percutaneous balloon angioplasty (PTCA)-without stent implantation-allows safe transition ... Full text Link to item Cite

Standardized cardiovascular data for clinical research, registries, and patient care: a report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure project.

Journal Article J Am Coll Cardiol · May 7, 2013 Relatively little attention has been focused on standardization of data exchange in clinical research studies and patient care activities. Both are usually managed locally using separate and generally incompatible data systems at individual hospitals or cl ... Full text Link to item Cite

Research management team (RMT): a model for research support services at Duke University.

Journal Article Clin Transl Sci · December 2012 Collecting and managing data for clinical and translational research presents significant challenges for clinical and translational researchers, many of whom lack needed access to data management expertise, methods, and tools. At many institutions, funding ... Full text Link to item Cite

Current state of information technologies for the clinical research enterprise across academic medical centers.

Journal Article Clin Transl Sci · June 2012 Information technology (IT) to support clinical research has steadily grown over the past 10 years. Many new applications at the enterprise level are available to assist with the numerous tasks necessary in performing clinical research. However, it is not ... Full text Link to item Cite

Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.

Journal Article Am J Cardiovasc Drugs · April 1, 2012 Antithrombotic therapy is imperative in the management of patients presenting with an acute coronary syndrome (ACS). The combination of antiplatelet therapy in conjunction with antithrombotic therapy has become the standard of care in improving the morbidi ... Full text Link to item Cite

Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial).

Journal Article Am J Cardiol · March 15, 2012 The prognostic significance of postprocedure sustained ventricular tachycardia or ventricular fibrillation (VT/VF) in patients undergoing primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) has rarely be ... Full text Link to item Cite

Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions.

Journal Article Catheter Cardiovasc Interv · March 1, 2012 OBJECTIVES: This study sought to assess the benefits of a coronary chronic total occlusion CTO recanalization after adjusting for the case-mix and the propensity to undergo the CTO intervention in a population of patients with stable coronary artery diseas ... Full text Link to item Cite

Usability evaluation of a personal health record.

Journal Article AMIA Annu Symp Proc · 2011 The electronic personal health record (PHR) has been championed as a mediator of patient-centered care, yet its usability and utility to patients, key predictors of success, have received little attention. Human-centered design (HCD) offers validated metho ... Link to item Cite

Economic analysis of centralized vs. decentralized electronic data capture in multi-center clinical studies.

Journal Article Stud Health Technol Inform · 2011 BACKGROUND: New data management models are emerging in multi-center clinical studies. We evaluated the incremental costs associated with decentralized vs. centralized models. METHODS: We developed clinical research network economic models to evaluate three ... Link to item Cite

Primary Angioplasty in Acute Myocardial Infarction

Book · October 28, 2010 Publication of the first edition of Primary Angioplasty in Acute Myocardial Infarction in 2002 to some extent anticipated the widespread acceptance of primary percutaneous coronary intervention as the standard of care. ... Cite

Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Journal Article J Am Coll Cardiol · April 6, 2010 OBJECTIVES: The aim of this study was to determine the impact of delay to angioplasty in patients with acute coronary syndromes (ACS). BACKGROUND: There is a paucity of data on the impact of delays to percutaneous coronary intervention (PCI) in patients wi ... Full text Link to item Cite

Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.

Journal Article Circulation · February 16, 2010 Featured Publication BACKGROUND: Eptifibatide reduces major adverse cardiac events in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). Intracoronary bolus administration of eptifibatide may result in higher levels of platelet glycopro ... Full text Link to item Cite

Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]).

Journal Article Am J Cardiol · January 1, 2010 In the Occluded Artery Trial (OAT), percutaneous coronary intervention (PCI) of an infarct-related artery on days 3 to 28 after acute myocardial infarction was of no benefit compared to medical therapy alone. The present analysis was conducted to determine ... Full text Link to item Cite

Prasugrel: Clinical development and therapeutic application.

Journal Article Adv Ther · November 2009 Featured Publication Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention. Despite the proven benefits, clear limitations of clopidogrel exist. Prasu ... Full text Link to item Cite

Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.

Journal Article J Interv Cardiol · August 2009 The impact of thienopyridine administration prior to primary stenting in acute myocardial infarction (AMI) has not been well studied. We therefore examined the database from the prospective, multicenter, controlled CADILLAC trial in which 1,036 patients we ... Full text Link to item Cite

Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.

Journal Article Can J Cardiol · August 2009 BACKGROUND: The Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial compared the use of eptifibatide with placebo in 2064 coronary intervention patients. It was previously reported that Canadian patien ... Full text Link to item Cite

Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.

Journal Article JACC Cardiovasc Interv · July 2009 OBJECTIVES: We sought to determine the relationship between red blood cell (RBC) transfusion and clinical outcomes in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). BACKGROUND: The implications o ... Full text Link to item Cite

Primary Coronary Intervention: The Technical Approach

Chapter · April 29, 2009 Publication of the first edition of Primary Angioplasty in Acute Myocardial Infarction in 2002 to some extent anticipated the widespread acceptance of primary percutaneous coronary intervention as the standard of care. ... Cite

Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.

Journal Article Circ Cardiovasc Interv · February 2009 Featured Publication BACKGROUND: Only limited data describe relationships between stent parameters (length and diameter), adverse events after percutaneous coronary intervention, and effects of platelet glycoprotein IIb/IIIa blockade by stent parameters. METHODS AND RESULTS: I ... Full text Link to item Cite

Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.

Journal Article Catheter Cardiovasc Interv · December 1, 2008 OBJECTIVE: The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI). BACKGROUND: Prior studies have yielded conflict ... Full text Link to item Cite

Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions.

Journal Article Am Heart J · May 2008 Featured Publication In 2006, the American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions published the 2005 update of the evidence-based guidelines for the treatment of patients undergoing percutaneous coronary intervention (PC ... Full text Link to item Cite

Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites.

Journal Article Am J Cardiol · February 15, 2008 The development of atrial fibrillation (AF) in cardiac patients is multifactorial, including not well defined genetic factors. To determine if Asian ethnicity is associated with the development of AF in patients with coronary disease, a meta-analysis was c ... Full text Link to item Cite

Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.

Journal Article Am J Cardiol · November 1, 2007 Featured Publication Adjunctive pharmacotherapy for stabilizing patients with acute coronary syndrome/non-ST-segment elevation myocardial infarction (ACS/NSTEMI) and for subsequent percutaneous coronary intervention (PCI) includes a combination of anticoagulant and antiplatele ... Full text Link to item Cite

Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.

Journal Article Eur Heart J · July 2007 AIMS: We sought to investigate the impact of multivessel coronary artery disease (CAD) on reperfusion success and prognosis following primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). The influence of mult ... Full text Link to item Cite

Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.

Journal Article Catheter Cardiovasc Interv · July 1, 2007 Featured Publication OBJECTIVES: This analysis sought to investigate the complementary effect of thienopyridine pretreatment and platelet glycoprotein (GP) IIb/IIIa integrin blockade in coronary stent intervention. BACKGROUND: Definitive evidence supporting combined antiplatel ... Full text Link to item Cite

Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).

Journal Article Am J Cardiol · April 15, 2007 Despite the well-recognized role of platelets in the pathogenesis of acute myocardial infarction (AMI) and in the vascular responses to angioplasty, the relation between platelet count and outcomes after primary percutaneous coronary intervention (PCI) in ... Full text Link to item Cite

Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty.

Journal Article Am J Cardiol · April 15, 2007 We examined whether leukocytosis is a negative prognostic factor in patients who underwent primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), and, if so, determined whether it is associated with impaired myocardial perf ... Full text Link to item Cite

Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.

Journal Article Am J Cardiol · January 15, 2007 We evaluated the utility of a routine postprocedure course of unfractionated heparin after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in patients not receiving glycoprotein IIb/IIIa inhibitors. In the CADILLAC st ... Full text Link to item Cite

Clinical implications of vulnerable plaque.

Journal Article Future Cardiol · November 2006 In many individuals, the first indicator of atherosclerosis is an acute heart attack, which is often fatal. Despite innovations in medical therapy and interventional cardiology techniques, coronary artery disease continues to be the leading cause of death ... Full text Link to item Cite

The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.

Journal Article J Am Coll Cardiol · October 17, 2006 OBJECTIVES: We aimed to evaluate clinical outcomes among peripheral arterial disease (PAD) patients following percutaneous coronary intervention (PCI). BACKGROUND: A significant proportion of patients with coronary artery disease undergoing PCI have concom ... Full text Link to item Cite

After fibrinolysis: is cardiac catheterization the answer?

Journal Article J Am Coll Cardiol · October 3, 2006 Featured Publication Full text Link to item Cite

Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.

Journal Article J Interv Cardiol · October 2006 Featured Publication Substantial controversy exists regarding the optimal pharmacologic cocktail for percutaneous coronary intervention (PCI). The most common approach typically includes aspirin, clopidogrel, unfractionated heparin (or enoxaparin), and (variably) a glycoprotei ... Full text Link to item Cite

Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina.

Journal Article J Thromb Thrombolysis · August 2006 BACKGROUND: Distal embolization of thrombotic debris may occur during and after percutaneous coronary intervention (PCI) for acute coronary syndromes. This may lead to impaired microvascular perfusion, myocardial infarction and increased morbidity and mort ... Full text Link to item Cite

Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).

Journal Article Am J Cardiol · August 1, 2006 We determined the outcomes of patients with acute ST-segment elevation (STE) myocardial infarction (STEMI) and non-STEMI (NSTEMI) after primary percutaneous coronary intervention (PCI). The prognosis after primary PCI in STEMI has been extensively studied ... Full text Link to item Cite

Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.

Journal Article Am Heart J · June 2006 BACKGROUND: The association between infarct artery location, reperfusion success, and clinical outcomes after primary percutaneous coronary intervention (PCI) has not been characterized. We examined the infarct artery-specific impact of epicardial and myoc ... Full text Link to item Cite

Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial.

Journal Article Am Heart J · June 2006 BACKGROUND: The impact of treatment delays on outcomes after primary percutaneous coronary intervention for acute myocardial infarction is controversial. METHODS: The CADILLAC trial randomized 2082 patients with acute myocardial infarction to stenting vers ... Full text Link to item Cite

Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction.

Journal Article J Am Coll Cardiol · March 7, 2006 OBJECTIVES: We examined the prognostic implications of the absolute level and rate of increase of creatine kinase (CK) elevation after primary percutaneous coronary intervention (PCI). BACKGROUND: Peak creatine kinase (CK(peak)) and the rate of CK increase ... Full text Link to item Cite

Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.

Journal Article J Am Coll Cardiol · February 21, 2006 Featured Publication OBJECTIVES: In order to determine a differential benefit from treatment, we compared the long-term outcome of high-risk versus low-risk patients and evaluated survival free from death or myocardial infarction at one year. BACKGROUND: Newer anticoagulant st ... Full text Link to item Cite

From clinical pathways to CPOE: challenges and opportunities in standardization and computerization of postoperative orders for total joint replacement.

Journal Article J Surg Orthop Adv · 2006 Clinical pathways, or caremaps, have become key tools for hospitals to streamline patient care. They are most applicable in situations where a high degree of predictability regarding treatment and/or diagnostic intervention is expected. Perceived advantage ... Link to item Cite

Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction.

Journal Article Am Heart J · January 2006 BACKGROUND: The prognostic importance of obesity after primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) is unknown. We therefore sought to investigate the impact of body mass index (BMI) in patients with A ... Full text Link to item Cite

Quantitative and qualitative comparison of text-based and graphical user interfaces for Computerized Provider Order Entry.

Journal Article AMIA Annu Symp Proc · 2006 Featured Publication Limited prospective data exist that define advantages and disadvantages of text-based versus graphical user interfaces in Computerized Provider Order Entry (CPOE). We created a single set of admission orders in both formats and, using a randomized crossove ... Link to item Cite

Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry).

Journal Article Am J Cardiol · December 15, 2005 Baseline features, management, and outcomes of patients who had acute myocardial infarction (AMI) and were excluded from randomized trials of primary percutaneous coronary intervention (PCI) have not been well described. We examined the baseline features a ... Full text Link to item Cite

Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.

Journal Article Am J Cardiol · August 15, 2005 Thrombocytopenia that develops after percutaneous coronary intervention (PCI) may result in hemorrhagic complications, requirement for blood product transfusions, and potentially thrombotic or ischemic complications. The incidence and prognostic significan ... Full text Link to item Cite

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited.

Journal Article Am Heart J · August 2005 OBJECTIVES: We sought to determine the relationship between cigarette smoking and outcomes after mechanical reperfusion therapy in acute myocardial infarction (AMI). BACKGROUND: Prior studies have found that smokers with AMI have lower mortality rates and ... Full text Link to item Cite

Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction.

Journal Article Am J Cardiol · August 1, 2005 We evaluated the prognostic effect of baseline left ventricular function and the determinants of its recovery after acute myocardial infarction (AMI) treated by primary angioplasty. Left ventriculography was performed during the index procedure in 1,620 of ... Full text Link to item Cite

Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial.

Journal Article J Invasive Cardiol · July 2005 Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention, rather than as prophylactic treatment. We sought to identify the characteristics and outcomes of ... Link to item Cite

Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.

Journal Article J Am Coll Cardiol · May 3, 2005 OBJECTIVES: We sought to develop a simple risk score for predicting mortality after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). BACKGROUND: Accurate risk stratification after primary PCI is important. Previous ri ... Full text Link to item Cite

Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital.

Journal Article Am J Cardiol · May 1, 2005 Despite guidelines to the contrary, limited numbers of elective percutaneous coronary intervention (PCI) procedures without on-site surgical backup are being performed, particularly in Europe and Canada. In the United States, many hospitals are considering ... Full text Link to item Cite

Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

Journal Article JAMA · April 13, 2005 CONTEXT: The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of debate. OBJECTIVE: To combine data from all randomized trials conducted with abciximab in STEMI. DATA SOURCES: Formal searches of e ... Full text Link to item Cite

Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Journal Article Circulation · April 5, 2005 BACKGROUND: Women with acute myocardial infarction (AMI) undergoing primary angioplasty have higher rates of morbidity and mortality than do men. Whether contemporary interventional treatment strategies have improved outcomes for women compared with men is ... Full text Link to item Cite

Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.

Journal Article Eur Heart J · April 2005 AIMS: ST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute myocardial infarction (AMI). We sought to determine whether the combination of SigmaSTR and MB after ... Full text Link to item Cite

Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.

Journal Article Catheter Cardiovasc Interv · March 2005 The objectives of this study were to explore the rate of vascular complications using closure devices (CDs) vs. manual compression (MC) among percutaneous coronary intervention (PCI) patients receiving enoxaparin, clopidogrel, aspirin, and GP IIb/IIIa inhi ... Full text Link to item Cite

Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.

Journal Article J Am Coll Cardiol · February 15, 2005 OBJECTIVES: We investigated the impact of diabetes mellitus on myocardial perfusion after primary percutaneous coronary intervention (PCI) utilizing myocardial blush grade (MBG) and ST-segment elevation resolution (STR). BACKGROUND: Diabetes is an independ ... Full text Link to item Cite

Stroke after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 2005 Link to item Cite

Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).

Journal Article Am J Cardiol · January 1, 2005 We sought to determine the benefits of stent implantation and abciximab in patients with diabetes mellitus and acute myocardial infarction (AMI) who underwent primary angioplasty. In a 2-by-2 factorial design, 2,082 patients with AMI were randomly assigned ... Full text Link to item Cite

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.

Journal Article Am Heart J · January 2005 BACKGROUND: Adjunctive pharmacotherapy during percutaneous coronary intervention (PCI) has historically consisted of a regimen of antiplatelet agents accompanied by an antithrombin agent, typically unfractionated heparin. Paradoxically, unfractionated hepa ... Full text Link to item Cite

Clinical characteristics of hypotension in patients with acute aortic dissection

Journal Article American Journal of Cardiology · January 1, 2005 To evaluate the clinical characteristics, risk factors, and outcomes of hypotension in unselected patients who had acute aortic dissection (AAD), we studied 1,073 such patients who were enrolled in the International Registry of Acute Aortic Dissection betw ... Full text Cite

Which is the true channel?

Journal Article J Invasive Cardiol · December 2004 Link to item Cite

A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.

Journal Article Can J Cardiol · November 2004 BACKGROUND: Practice patterns for percutaneous coronary interventions (PCIs) may differ between Canada and the United States. Few data are available comparing PCI outcomes between the two countries in the era of coronary stenting and adjunctive glycoprotei ... Link to item Cite

Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.

Journal Article Am J Cardiol · October 15, 2004 We examined the effect of aspirin use at the time of admission and discharge from a large-scale, prospective multicenter trial of patients who had been treated with primary percutaneous coronary intervention in acute myocardial infarction. ... Full text Link to item Cite

Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).

Journal Article Am J Cardiol · October 15, 2004 We sought to identify the predictors and clinical outcomes of early thrombosis after primary angioplasty and stenting for acute myocardial infarction (AMI). Little is known about the correlates and prognosis of acute and subacute thromboses after percutane ... Full text Link to item Cite

Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).

Journal Article Am J Cardiol · October 1, 2004 Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no ... Full text Link to item Cite

Implications of stroke after primary angioplasty in acute myocardial infarction.

Conference AMERICAN JOURNAL OF CARDIOLOGY · September 30, 2004 Link to item Cite

Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Journal Article Circulation · September 21, 2004 BACKGROUND: Biological age is a strong determinant of prognosis in patients with acute myocardial infarction (AMI). We sought to examine the impact of age after primary percutaneous coronary intervention in AMI and to determine whether routine coronary ste ... Full text Link to item Cite

Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Journal Article J Am Coll Cardiol · September 15, 2004 OBJECTIVE: This study was done to assess and compare the prognostic significance of multiple methods for measuring ST-segment elevation resolution (STR) following primary percutaneous coronary intervention (PCI). BACKGROUND: Resolution of ST-segment elevat ... Full text Link to item Cite

Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial).

Journal Article Am J Cardiol · September 1, 2004 In 2,082 patients in the CADILLAC trial, the outcomes of patients presenting during peak hours were compared with those presenting during peak hours (Monday to Friday 8a.m. to 8 p.m., n = 1,047, 51%) were compared with those of patients presenting during o ... Full text Link to item Cite

Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.

Journal Article J Invasive Cardiol · September 2004 We determined the timing of ischemic complications within 30 days after percutaneous coronary intervention (PCI) in patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Complications (death ... Link to item Cite

Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.

Journal Article J Am Coll Cardiol · August 4, 2004 OBJECTIVES: We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). BACKGROUND: The prognostic importance of anemia on primary PCI outcomes is unknown. ME ... Full text Link to item Cite

Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.

Journal Article J Am Coll Cardiol · July 21, 2004 OBJECTIVES: We sought to determine the prognostic importance of myocardial reperfusion after various contemporary interventional strategies in patients with acute myocardial infarction (AMI). BACKGROUND: The frequency, correlates, and clinical implications ... Full text Link to item Cite

Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.

Journal Article Am J Cardiol · July 15, 2004 Increased inflammatory markers are associated with a poor prognosis after percutaneous coronary intervention. Leukocytes play a key role in inflammation, and an increase in white blood cell (WBC) counts is a nonspecific marker of inflammation. In patients ... Full text Link to item Cite

Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.

Journal Article Am J Cardiol · July 1, 2004 Anemia and renal insufficiency impart an increased risk of mortality in patients with congestive heart failure. There is a paucity of data on the mortality hazard associated with anemia and renal insufficiency in patients undergoing percutaneous coronary i ... Full text Link to item Cite

Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction.

Journal Article J Am Coll Cardiol · May 19, 2004 OBJECTIVES: We sought to examine the effect of intravenous beta-blockers administered before primary percutaneous coronary intervention (PCI) on survival and myocardial recovery after acute myocardial infarction (AMI). BACKGROUND: Studies of primary PCI bu ... Full text Link to item Cite

Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Journal Article J Am Coll Cardiol · April 21, 2004 OBJECTIVES: We sought to determine the prognostic importance of mitral regurgitation (MR) in patients undergoing percutaneous coronary intervention for acute myocardial infarction (AMI). BACKGROUND: Mitral regurgitation has been associated with a poor prog ... Full text Link to item Cite

Final results of the ReoPro readministration registry.

Journal Article Am J Cardiol · April 15, 2004 Because of its potential for antigenicity, theoretical concerns related to readministration of abciximab have been raised. We conducted the ReoPro Readministration Registry to assess the efficacy and safety of abciximab readministration. A total of 1,342 p ... Full text Link to item Cite

Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial.

Journal Article Am Heart J · April 2004 BACKGROUND: Age is a strong independent predictor of outcomes after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Whether lower rates of reperfusion success contribute to the poor prognosis in elderly patients is u ... Full text Link to item Cite

Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era.

Journal Article J Interv Cardiol · April 2004 Since the introduction of platelet glycoprotein (GP) IIb/IIIa inhibitors, reports of vascular complications after percutaneous coronary intervention (PCI) have focused on bleeding and the need for surgical repair, whereas specific major vascular complicati ... Full text Link to item Cite

Coronary artery stenting and eptifibatide treatment in diabetes

Journal Article Cardiology Review · April 1, 2004 We evaluated data from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial regarding the outcomes of diabetic patients using eptifibatide, a small molecule glycoprotein IIb/IIIa inhibitor. Eptifibatide treatmen ... Cite

Reply

Journal Article Journal of the American College of Cardiology · April 2004 Full text Cite

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

Journal Article Am Heart J · March 2004 BACKGROUND: Investigations of glycoprotein (GP) IIb/IIIa inhibition in primary percutaneous coronary intervention (PCI) have suggested the efficacy of abciximab in improving clinical and angiographic outcomes, but sample-size limitations and variability in ... Full text Link to item Cite

Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).

Journal Article Am J Cardiol · February 1, 2004 The importance of sustained patency of the infarct-related artery after primary percutaneous coronary intervention for acute myocardial infarction is controversial. We examined serial measures of left ventricular function and clinical outcomes in 280 patie ... Full text Link to item Cite

GP IIb/IIIa blockade in elective percutaneous coronary intervention.

Journal Article Curr Pharm Des · 2004 Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb/IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available ... Full text Link to item Cite

Trial finds adding abciximab to stent reperfusion improves survival in acute myocardial infarction

Journal Article Evidence-based Cardiovascular Medicine · January 1, 2004 Full text Cite

Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.

Journal Article Circulation · December 9, 2003 BACKGROUND: Both stenting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing primary angioplasty for acute myocardial infarction (AMI). However, the cost-effectiveness of these strategies is unknown. METHODS AND RESU ... Full text Link to item Cite

Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.

Journal Article Circulation · December 2, 2003 BACKGROUND: The prognostic importance of renal insufficiency (RI) in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) has not been well characterized. METHODS AND RESULTS: PCI was performed in 2082 ... Full text Link to item Cite

Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).

Journal Article Am J Cardiol · November 1, 2003 The utility of glycoprotein IIb/IIIa receptor inhibitors as a "bail-out" modality after unsuccessful primary percutaneous coronary intervention for acute myocardial infarction is unknown. In the CADILLAC trial, of 1,030 control patients, 62 patients (6.0%) ... Full text Link to item Cite

Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial).

Journal Article Am J Cardiol · November 1, 2003 The results of bail-out stenting after unsuccessful primary balloon angioplasty compared with routine stenting or successful balloon angioplasty in acute myocardial infarction are unknown. In the CADILLAC trial, 168 of 1,044 patients (16.1%) randomized to ... Full text Link to item Cite

Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).

Journal Article Am J Cardiol · October 1, 2003 Early complications may hamper efforts to hasten discharge after primary percutaneous coronary intervention (PCI) for myocardial infarction (MI). Glycoprotein IIb/IIIa inhibitors, by reducing early recurrent ischemia, may aid in these efforts. We examined ... Full text Link to item Cite

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.

Journal Article Heart · October 2003 BACKGROUND: Raised inflammatory markers are associated with worse outcome after percutaneous coronary interventions (PCI). An increase in the white blood cell (WBC) count is a non-specific response to inflammation. We hypothesised that a raised baseline WB ... Full text Link to item Cite

A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study.

Journal Article J Am Coll Cardiol · September 17, 2003 OBJECTIVES: The aim of this study was to discern a target range of anticoagulation for enoxaparin during percutaneous coronary intervention (PCI) as measured by the Rapidpoint ENOX (Pharmanetics Inc., Morrisville, North Carolina), a new point-of-care test. ... Full text Link to item Cite

Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.

Journal Article J Am Coll Cardiol · September 17, 2003 OBJECTIVES: We sought to compare outcomes between patients with acute myocardial infarction (AMI) undergoing percutaneous transluminal coronary angioplasty (PTCA) with an optimal or "stent-like" result versus patients who underwent routine stent placement. ... Full text Link to item Cite

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Journal Article Circulation · September 16, 2003 BACKGROUND: Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment. However, variations ... Full text Link to item Cite

Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.

Journal Article Am J Cardiol · September 15, 2003 We performed a cumulative meta-analysis of available studies to evaluate the effect of intravenous platelet glycoprotein (GP) IIb/IIIa antagonists on survival at 30 days and 6 months after percutaneous coronary intervention (PCI). Compounds that block the ... Full text Link to item Cite

Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).

Journal Article Am J Cardiol · September 15, 2003 Myocardial ischemic injury complicating acute myocardial infarction (AMI) and coronary revascularization procedures remains an unresolved clinical dilemma. In preclinical studies, treatment with pyridoxal-5'-phosphate monohydrate (MC-1), a vitamin B6 metab ... Full text Link to item Cite

Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials.

Journal Article J Interv Cardiol · August 2003 The effects of beta blocker therapy in the settings of heart failure and coronary artery disease have been well described, although little data exist in patients presenting with acute coronary syndromes undergoing percutaneous coronary intervention. The cu ... Full text Link to item Cite

Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.

Journal Article J Interv Cardiol · April 2003 Rarely is it straightforward to specify the design and parameters of a clinical trial investigating an alternative therapy where effective therapies already exist. If existing therapeutic interventions are highly efficacious, safe, inexpensive, and firmly ... Full text Link to item Cite

Abciximab readministration: Final results of the Reopro(fi) read ministration registry

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · March 19, 2003 Link to item Cite

Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.

Journal Article J Am Coll Cardiol · February 5, 2003 OBJECTIVES: We evaluated the relationship between the degree of heparin anticoagulation and clinical efficacy and bleeding in patients undergoing contemporary percutaneous coronary intervention (PCI) with stent implantation. BACKGROUND: Despite universal a ... Full text Link to item Cite

Reply

Journal Article The American Journal of Cardiology · February 2003 Full text Cite

Implementing a New Method for Activated Clotting Time

Journal Article Plastic Surgical Nursing · January 1, 2003 Point-of-care determination of the activated clotting time (ACT) has become the standard of care in a number of clinical situations. The authors converted from ACT done by the Hemochron 801 analyzer, which uses tubes containing either celite, kaolin, or gl ... Full text Cite

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial).

Journal Article Am J Cardiol · January 1, 2003 The role of platelet glycoprotein IIb/IIIa inhibitor therapy in patients with mild renal impairment is not well characterized. Our objective was to explore the associations of creatinine clearance (CrCl) with outcomes in a trial of eptifibatide therapy in ... Full text Link to item Cite

Efficacy and safety of minimal dose (

Journal Article The American journal of cardiology · January 2003 Abciximab decreases adverse cardiac ischemic events, and in some subgroups, decreases the need for revascularization after percutaneous coronary intervention (PCI). However, abciximab may cause bleeding complications and thrombocytopenia after PCI. We hypo ... Cite

Double negatives.

Journal Article Am Heart J · January 2003 Full text Link to item Cite

Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.

Journal Article Dev Biol (Basel) · 2003 The clinical consequences of immune antibodies generated to abciximab (ReoPro) and infliximab (Remicade) are described. Abciximab, a chimaeric Fab fragment that binds to the beta3 integrin of the GPIIb/IIIa and alphavbeta3 receptors on human platelets, is ... Link to item Cite

Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention.

Journal Article Am J Cardiol · January 1, 2003 Abciximab decreases adverse cardiac ischemic events, and in some subgroups, decreases the need for revascularization after percutaneous coronary intervention (PCI). However, abciximab may cause bleeding complications and thrombocytopenia after PCI. We hypo ... Full text Link to item Cite

Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.

Journal Article Catheter Cardiovasc Interv · December 2002 We analyzed vascular access site bleeding from the EPIC, EPILOG, and EPISTENT trials to quantify the decrease in vascular bleeding complications in these three trials, especially those attributable to abciximab. The incidence of combined major and minor va ... Full text Link to item Cite

Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).

Journal Article Am J Cardiol · November 1, 2002 In the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT), abciximab reduced ischemic complications of stent implantation at 30 days and 6 months. The responsible mechanisms remain unclear. We sought to determine if abciximab decreases ... Full text Link to item Cite

Eptifibatide in percutaneous coronary intervention. A review.

Journal Article Minerva Cardioangiol · October 2002 Percutaneous coronary angioplasty and stenting is widely used for the treatment of patients with coronary artery disease. Glycoprotein (GP) IIb-IIIa inhibitors represent a new class of drugs with proven efficacy in reducing ischemic complications of patien ... Link to item Cite

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

Journal Article J Am Coll Cardiol · September 18, 2002 OBJECTIVE: The study was done to determine whether eptifibatide, a platelet glycoprotein (GP) IIb/IIIa antagonist, prevents ischemic complications following percutaneous coronary interventions (PCIs) in women as well as in men. BACKGROUND: Eptifibatide red ... Full text Link to item Cite

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.

Journal Article Circulation · September 17, 2002 BACKGROUND: The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established. METHODS AND RESULTS: W ... Full text Link to item Cite

Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).

Journal Article Am J Cardiol · September 15, 2002 For patients undergoing nonurgent coronary stent implantation, blockade of the glycoprotein IIb/IIIa receptor with eptifibatide reduces the incidence of ischemic complications. We evaluated the interaction of eptifibatide with diabetes in patients who unde ... Full text Link to item Cite

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.

Journal Article Circulation · September 3, 2002 BACKGROUND: Restenosis after percutaneous coronary intervention (PCI) is a major problem affecting 15% to 30% of patients after stent placement. No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. ... Full text Link to item Cite

Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications.

Journal Article Am Heart J · September 2002 BACKGROUND: Approximately 50% of percutaneous coronary interventions in the United States are performed with unfractionated heparin and no IIb/IIIa agent. The operator must weigh the risks and benefits of more intensive anticoagulation during these percuta ... Full text Link to item Cite

Coronary artery stents: evaluating new designs for contemporary percutaneous intervention.

Journal Article Catheter Cardiovasc Interv · August 2002 Intracoronary stents have markedly improved the short- and long-term safety and efficacy of percutaneous coronary intervention by improving acute gains in luminal dimensions, decreasing abrupt vessel occlusion, and reducing restenosis. At present, nearly 9 ... Full text Link to item Cite

Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.

Journal Article Expert Opin Pharmacother · August 2002 The platelet glycoprotein (GP) IIb/IIIa integrin plays a key role in mediating platelet aggregation. Blockade of the platelet GP IIb/IIIa receptor prevents arterial thrombosis in animal models much better than does aspirin. Among the most specific inhibito ... Full text Link to item Cite

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.

Journal Article Am J Med · July 2002 There is considerable evidence supporting the use of platelet glycoprotein IIb/IIIa inhibitors to reduce ischemic complications of percutaneous coronary revascularization. However, long-term follow-up has been limited. In three large-scale randomized trial ... Full text Link to item Cite

Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

Journal Article Am Heart J · July 2002 BACKGROUND: A simple device to rapidly evaluate platelet function may aid in optimizing glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention (PCI). We prospectively studied platelet function in 250 patients receiving abciximab or epti ... Full text Link to item Cite

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

Journal Article N Engl J Med · March 28, 2002 BACKGROUND: As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death, reinfarction, and stroke, but recurrent ischemia, restenosis, and reocclusion of the ... Full text Link to item Cite

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.

Journal Article JAMA · February 6, 2002 CONTEXT: In the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial, treatment with eptifibatide, a platelet glycoprotein IIb/IIIa integrin blocker, was found to reduce the ischemic complications of nonurgent coron ... Full text Link to item Cite

Primary Angioplasty in Acute Myocardial Infarction

Book · 2002 Leading investigators and highly experienced clinicians collect and summarize the world's literature and augment this with practical wisdom concerning this critically important form of care, including its technical, professional, and ... ... Cite

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.

Journal Article Am Heart J · January 2002 BACKGROUND: The etiology of creatine kinase-myocardial band (CK-MB) release after percutaneous coronary intervention (PCI) remains unclear. The goal of this study was to evaluate the relationship of both epicardial and tissue level perfusion at the complet ... Full text Link to item Cite

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

Journal Article Am J Cardiol · November 15, 2001 This study describes the dose-exploration phase of the PRIDE trial, an investigation of the clinical pharmacology of higher dose eptifibatide in patients who underwent elective percutaneous coronary intervention (PCI). Outcomes of treatment with the platel ... Full text Link to item Cite

Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.

Journal Article Am J Cardiol · November 1, 2001 We sought to determine whether eptifibatide reduces elevation of creatine kinase (CK)-MB isoenzyme release during coronary intervention by preventing angiographic complications, by minimizing the sequelae of angiographic complications once they occur, or b ... Full text Link to item Cite

ESPRIT in context: pharmacology matters!

Journal Article Eur Heart J · November 2001 Full text Link to item Cite

Does primary stenting benefit proximal LAD infarction? The CADILLAC trial.

Journal Article AMERICAN JOURNAL OF CARDIOLOGY · September 11, 2001 Link to item Cite

Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.

Journal Article J Am Coll Cardiol · September 2001 OBJECTIVES: We sought to determine whether eptifibatide decreases the incidence of in-laboratory angiographic complications and to determine the relationship of angiographically evident complications to elevations of creatine kinase-MB (CK-MB) enzyme level ... Full text Link to item Cite

Abciximab readministration: results of the ReoPro Readministration Registry.

Journal Article Circulation · August 21, 2001 BACKGROUND: Platelet glycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of percutaneous coronary intervention. This registry was conducted to characterize the effects of repeated administration of abciximab during interve ... Full text Link to item Cite

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.

Journal Article Circulation · July 24, 2001 BACKGROUND: Pharmacodynamics of eptifibatide, a cyclic heptapeptide antagonist of platelet glycoprotein IIb/IIIa, are substantially altered by anticoagulants that chelate calcium, resulting in overestimation ex vivo of the in vivo effects of this agent. We ... Full text Link to item Cite

Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.

Journal Article JAMA · July 4, 2001 CONTEXT: Abciximab, a potent inhibitor of the platelet glycoprotein IIb/IIIa receptor, reduces thrombotic complications in patients undergoing percutaneous coronary intervention (PCI). Because of its potent inhibition of platelet aggregation, the effect of ... Full text Link to item Cite

No jacket required.

Journal Article J Invasive Cardiol · July 2001 Link to item Cite

Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes?

Journal Article J Am Coll Cardiol · June 1, 2001 OBJECTIVES: To predict which patients might not require stent implantation, we identified clinical and angiographic characteristics associated with repeat revascularization after standard balloon angioplasty. BACKGROUND: Stents reduce the risk of repeat re ... Full text Link to item Cite

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

Journal Article Circulation · May 29, 2001 BACKGROUND: The optimal level of platelet inhibition with a glycoprotein (GP) IIb/IIIa antagonist necessary to minimize thrombotic complications in patients undergoing a percutaneous coronary intervention (PCI) is currently unknown. METHODS AND RESULTS: Fi ... Full text Link to item Cite

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.

Journal Article JAMA · May 16, 2001 CONTEXT: The Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial showed the efficacy of adjunctive, double-bolus eptifibatide therapy in reducing ischemic complications of nonurgent coronary stent implantation at 4 ... Full text Link to item Cite

Eptifibatide in Percutaneous Coronary Intervention: The ESPRIT Trial Results.

Journal Article Curr Interv Cardiol Rep · February 2001 The ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) trial was a randomized, placebo-controlled trial to assess whether a novel, double-bolus dose of eptifibatide could improve the outcomes of patients undergoing coro ... Link to item Cite

Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.

Journal Article Am Heart J · February 2001 BACKGROUND: The platelet function analyzer PFA-100 (Dade Behring, Miami, Fla) evaluates platelet function by determining the time to occlusion of an aperture in a membrane coated with collagen and adenosine diphosphate or epinephrine as whole blood flows u ... Full text Link to item Cite

High-dose eptifibatide (Integrilin (R)) in coronary stent implantation: 1 year results of the ESPRIT trial

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 2001 Link to item Cite

Variations in event rates between Canada and United States in the EPISTENT trial

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 2001 Link to item Cite

Bailout platelet GP IIb/IIIa inhibition in coronary stent implantation: Observations from the ESPRIT trial

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 2001 Link to item Cite

Current multicentre studies with the excimer laser: design and aims.

Journal Article Lasers Med Sci · 2001 Excimer laser ablation to remove atherosclerotic plaque has been used for over a decade as a methodology to treat cardiovascular disease. Improvements in the technique and technology of excimer laser angioplasty, coupled with the recognition of new clinica ... Full text Link to item Cite

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.

Journal Article Lancet · December 16, 2000 BACKGROUND: The platelet glycoprotein IIb/IIIa inhibitors, although effective in reducing ischaemic complications of percutaneous coronary intervention, are used in few coronary stent implantation procedures. ESPRIT (Enhanced Suppression of the Platelet II ... Full text Link to item Cite

Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Journal Article Circulation · December 12, 2000 BACKGROUND: In the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade), abciximab administered with weight-adjusted heparin diminished the risk of ischemic complications within 30 days by 56% among patients un ... Full text Link to item Cite

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.

Journal Article Am Heart J · December 2000 BACKGROUND: Clinical trials of the glycoprotein (GP) IIb/IIIa inhibitors have shown that these potent antiplatelet agents are effective in reducing the ischemic complications of percutaneous coronary interventions. However, even though stents are now impla ... Full text Link to item Cite

Effects of 308 nanometer excimer laser energy on 316 L stainless-steel stents: implications for laser atherectomy of in-stent restenosis.

Journal Article J Invasive Cardiol · November 2000 PURPOSE: To determine the effects of the incidental exposure of stents to pulsed 308 nanometer ultraviolet excimer laser energy. METHODS: Five types of 316 L stainless-steel coronary stents were subjected to two types of study. First, for endurance testing ... Link to item Cite

Limitations in the APRDRG as a measure of severity

Journal Article CIRCULATION · October 31, 2000 Link to item Cite

Provisional stenting strategies: systematic overview and implications for clinical decision-making.

Journal Article J Am Coll Cardiol · October 2000 Coronary stents reduce the rates of abrupt closure, emergency coronary artery bypass graft surgery and restenosis, but do not prevent myocardial infarction or death at six months. The financial burden of increased stent use and the difficulty in managing i ... Full text Link to item Cite

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.

Journal Article Ann Thorac Surg · August 2000 BACKGROUND: Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required. METHODS: Outcomes were assessed among 85 pa ... Full text Link to item Cite

Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.

Journal Article J Am Coll Cardiol · August 2000 OBJECTIVES: We sought to determine the efficacy and safety of platelet glycoprotein IIb/IIIa receptor (GP IIb/IIIa) blockade with abciximab in women undergoing percutaneous coronary intervention. BACKGROUND: Although gender differences in response to plate ... Full text Link to item Cite

Update on Abciximab Readministration During Percutaneous Coronary Interventions.

Journal Article Curr Interv Cardiol Rep · August 2000 Abciximab is a monoclonal antibody fragment that blocks the platelet glycoprotein IIb/IIIa receptor and is increasingly used as an adjunct to percutaneous coronary intervention. Because some patients will return for additional revascularization procedures, ... Link to item Cite

Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer.

Journal Article Ann Thorac Surg · August 2000 BACKGROUND: Lymph node metastases are the most significant prognostic factor in localized non-small cell lung cancer (NSCLC). Nodal micrometastases may not be detected. Identification of the first nodal drainage site (sentinel node) may improve detection o ... Full text Link to item Cite

Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.

Journal Article Am Heart J · July 2000 BACKGROUND: Thrombocytopenia is infrequently associated with abciximab therapy but may contribute to hemorrhagic risk. Factors associated with development of thrombocytopenia, the role of weight-adjustment in concomitant heparin administration, and clinica ... Full text Link to item Cite

High-dose eptifibatide in elective coronary stenting: Results of the ESPRIT trial

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · July 1, 2000 Link to item Cite

The benefit of abciximab in percutaneous coronary revascularization is not device-specific.

Journal Article Am J Cardiol · May 1, 2000 Abciximab has been shown to decrease adverse outcomes after percutaneous coronary interventions, but it is unclear whether this beneficial effect is more or less pronounced with specific devices. This study sought to determine the relative magnitude of the ... Full text Link to item Cite

Local delivery of heparin post-PTCA: a multicenter randomized pilot study.

Journal Article Catheter Cardiovasc Interv · April 2000 Bailout stenting for major dissection and threatened closure has high rates of ischemic complications. We performed a randomized trial of local heparin delivery using the infusion sleeve before bailout stenting for suboptimal angioplasty results. In phase ... Full text Link to item Cite

Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents.

Journal Article Am J Cardiol · February 15, 2000 Although coronary stenting has been shown to be effective, retrospective studies have suggested that stents do not provide better results than angioplasty in small coronary arteries. We sought to examine procedural, in-hospital, and long-term outcomes of p ... Full text Link to item Cite

Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

Journal Article Am J Cardiol · February 15, 2000 We studied both the time course and risk factors for adverse clinical events after percutaneous coronary intervention (PCI). Such information is critical to clinical decision-making, but scant quantitative data exist to describe the time course of these ad ... Full text Link to item Cite

Efficacy of abciximab readministration in coronary intervention.

Journal Article Am J Cardiol · February 15, 2000 Abciximab, an Fab monoclonal antibody fragment that blocks the platelet glycoprotein IIb/IIIa receptor, is increasingly used as an adjunct to coronary intervention. Little is known, however, about the efficacy and safety of readministration of abciximab. T ... Full text Link to item Cite

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.

Journal Article Am Heart J · February 2000 Randomized clinical trials of glycoprotein IIb/IIIa integrin inhibition during percutaneous coronary intervention and as adjunctive treatment of acute coronary syndromes have shown impressive clinical efficacy in reducing the morbidity and mortality rates ... Full text Link to item Cite

Abciximab thrombocytopenia: Clinical correlates and outcomes

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 2000 Link to item Cite

The impact of abciximab on mortality after multivessel PCI: A striking effect in diabetics

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 2000 Link to item Cite

Treatment of Palmaz-Schatz in-stent restenosis: 6-Month clinical follow-up

Journal Article Journal of Interventional Cardiology · January 1, 2000 To identify predictors of Palmaz-Schatz in-stent restenosis and determine outcomes of treatment, we assessed 6-month outcomes in 402 patients who had coronary intervention with stent placement; 60 (15%) developed angiographic and clinical evidence of reste ... Full text Cite

Coronary intervention and glycoprotein IIb/IIIa integrin blockade.

Journal Article Coron Artery Dis · December 1999 In a few short years, platelet glycoprotein IIb/IIIa receptor antagonists have been developed from laboratory curiosities to critical treatment adjuncts to the successful performance of PCI. With more than 15,000 patients participating in trials of these a ... Full text Link to item Cite

Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa.

Journal Article Expert Opin Investig Drugs · November 1999 Platelet aggregation is intimately involved in the pathophysiology of acute coronary syndromes. Blockade of the platelet glycoprotein IIb/IIIa receptor, the mediator of platelet aggregation induced by all physiologic agonists, prevents arterial thrombosis ... Full text Link to item Cite

Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience.

Journal Article Am Heart J · November 1999 BACKGROUND: Rates of morbidity and mortality after interventional procedures are reported to be inversely associated with institutional volume. METHODS: This study assessed both procedural volume and academic status at the 82 US centers that participated i ... Full text Link to item Cite

Vale, warfarin: a stentorian farewell.

Journal Article Am Heart J · October 1999 Full text Link to item Cite

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

Journal Article N Engl J Med · July 29, 1999 BACKGROUND: Inhibition of the platelet glycoprotein IIb/IIIa receptor with the monoclonal-antibody fragment abciximab reduces the acute ischemic complications associated with percutaneous coronary revascularization, whereas coronary-stent implantation redu ... Full text Link to item Cite

Readministration of abciximab: interim report of the ReoPro readministration registry.

Journal Article Am Heart J · July 1999 Even with continued improvements in the technology of percutaneous coronary intervention (PCI), approximately 10% to 20% of patients undergoing PCI will require repeat procedures within 1 year. Furthermore, because of the chronic nature of coronary artery ... Full text Link to item Cite

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Journal Article Circulation · April 20, 1999 BACKGROUND: Blockade of the platelet glycoprotein IIb/IIIa receptor with the monoclonal antibody fragment abciximab was shown in a placebo-controlled randomized trial to reduce the incidence of acute ischemic complications within 30 days among a broad spec ... Full text Link to item Cite

Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators.

Journal Article Am Heart J · February 1999 BACKGROUND: Most analyses of complications after percutaneous coronary intervention have been limited to angiographic predictors of abrupt closure. We sought to determine the relation between baseline clinical and angiographic characteristics and clinical ... Full text Link to item Cite

Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.

Journal Article J Am Coll Cardiol · January 1999 OBJECTIVES: We examined the relations of elevated creatine kinase (CK) and its myocardial band isoenzyme (CK-MB) to clinical outcomes after percutaneous coronary intervention (PCI) in patients enrolled in Integrilin (eptifibatide) to Minimize Platelet Aggr ... Full text Link to item Cite

Safety issues surrounding use of platelet GP IIb/IIIa antagonists: Reversibility and readministration

Journal Article European Heart Journal, Supplement · January 1, 1999 The platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists abciximab, eptifibatide, and tirofiban have been shown to be safe and effective in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention. Conse ... Cite

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

Journal Article Circulation · December 22, 1998 BACKGROUND: Several platelet glycoprotein (GP) IIb/IIIa receptor antagonists have been evaluated in clinical trials. We conducted a systematic overview (meta-analysis) to assess the effect of these compounds on death, myocardial infarction (MI), and revasc ... Full text Link to item Cite

Glycoprotein IIb/IIIa integrin blockade.

Journal Article Circulation · December 8, 1998 Full text Link to item Cite

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Journal Article J Am Coll Cardiol · December 1998 OBJECTIVES: The trial was designed to assess the safety, pharmacodynamics and effects on reperfusion of the platelet glycoprotein (GP) IIb/IIIa inhibitor lamifiban when given with thrombolysis to patients with ST segment elevation acute myocardial infarcti ... Full text Link to item Cite

Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.

Journal Article J Am Coll Cardiol · November 15, 1998 OBJECTIVES: We investigated the hypothesis that abciximab might lead to a differential effect among patients with different lesion morphologies; hence, its cost/benefit ratio would be optimized if it were used selectively on the basis of baseline angiograp ... Full text Link to item Cite

Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.

Journal Article Am J Cardiol · November 1, 1998 Data from the 5 large randomized, double-blind, placebo-controlled trials that used glycoprotein IIb/IIIa inhibitors during percutaneous transluminal coronary angioplasty were pooled for a total of 10,691 patients. We found that the use of glycoprotein IIb ... Full text Link to item Cite

The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era.

Journal Article Can J Cardiol · August 1998 In autumn 1996, shortly after the platelet glycoprotein (GP) IIb/IIIa inhibitor abciximab was approved for clinical use by the Health Protection Branch of Health Canada, seven interventional cardiologists met in a roundtable forum to review the use of abci ... Link to item Cite

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.

Journal Article J Am Coll Cardiol · August 1998 OBJECTIVES: This study sought to determine the frequency of thrombocytopenia and its relation with clinical outcomes in high risk patients undergoing percutaneous coronary revascularization who received either the platelet glycoprotein (GP) IIb/IIIa recept ... Full text Link to item Cite

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Journal Article Lancet · July 11, 1998 BACKGROUND: Coronary stenting with use of heparin, aspirin, and ticlopidine for thromboprophylaxis is performed in more than 500,000 patients per year worldwide. We did a randomised controlled trial to assess the role of platelet glycoprotein-IIb/IIIa bloc ... Full text Link to item Cite

Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

Journal Article J Am Coll Cardiol · June 1998 OBJECTIVES: This study was designed to identify potential predictors of vascular access site (VAS) complications in the large-scale Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis (IMPACT) II trial, which studied angioplasty with versus ... Full text Link to item Cite

Laser wire for crossing chronic total occlusions: "learning phase" results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire.

Journal Article Cathet Cardiovasc Diagn · June 1998 The Prima laser guidewire system (Spectranectics Corp., Colorado Springs, CO) consists of an 0.018" hypotube containing a bundle of 45-microm optical fibers coupled to a pulsed excimer laser operating at a tip fluence of 60 ml/mm2 and a repetition rate ran ... Full text Link to item Cite

A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention.

Journal Article Am J Cardiol · April 15, 1998 This report details a prospectively randomized clinical trial comparing mechanical clamp compression to hand applied pressure for attaining vascular hemostasis after coronary intervention. Effectiveness was determined by comparing the incidence of femoral ... Full text Link to item Cite

Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.

Journal Article Circulation · March 10, 1998 BACKGROUND: The clinical and angiographic demographics of patients requiring unplanned coronary stent deployment and the optimal adjunct pharmacotherapy in this population are not well described. This report details the EPILOG trial experience with unplann ... Full text Link to item Cite

Abciximab Associated Thrombocytopenia: Evidence for a Complex Interaction With Heparin

Journal Article Journal of the American College of Cardiology · February 1998 Full text Cite

Safety of Readministration of Abciximab; Interim Results of the ReoPro Readministration Registry (R3)

Journal Article Journal of the American College of Cardiology · February 1998 Full text Cite

Eptifibatide pharmacokinetics in patients undergoing coronary angioplasty.

Journal Article CLINICAL PHARMACOLOGY & THERAPEUTICS · February 1, 1998 Link to item Cite

Complementarity of Stenting and Abciximab for Percutaneous Coronary Intervention

Journal Article Journal of the American College of Cardiology · February 1998 Full text Cite

Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.

Journal Article Tex Heart Inst J · 1998 During the past 2 decades, advances in molecular and cellular biology have greatly expanded our understanding of the critical role of platelets in the pathogenesis of acute coronary syndromes. This work has suggested that aggressive platelet inhibition mig ... Link to item Cite

Excimer laser coronary angioplasty: the New Approaches to Coronary Intervention (NACI) experience.

Journal Article Am J Cardiol · November 20, 1997 In the New Approaches to Coronary Intervention (NACI) registry, 887 patients were electively treated with excimer laser coronary angioplasty (ELCA) for coronary artery disease. The Advanced Interventional System (AIS) system was used in 487 cases; the Spec ... Full text Link to item Cite

Acute profound thrombocytopenia after c7E3 Fab therapy.

Journal Article Circulation · November 18, 1997 Link to item Cite

Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

Journal Article Am J Cardiol · August 18, 1997 Formation of platelet-rich thrombus superimposed on ruptured atherosclerotic plaque has been implicated in the development of myocardial ischemia and its clinical manifestations. The platelet glycoprotein (GP) IIb-IIIa receptor is the final common pathway ... Full text Link to item Cite

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Journal Article JAMA · August 13, 1997 CONTEXT: Abciximab, a monoclonal antibody fragment against the platelet receptor alphaIIb beta3 integrin, prevents platelet aggregation. A randomized, placebo-controlled study showed that abciximab improves outcomes for patients undergoing percutaneous cor ... Full text Link to item Cite

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Journal Article N Engl J Med · June 12, 1997 BACKGROUND: Blockade of the platelet glycoprotein IIb/IIIa receptor with abciximab (a monoclonal-antibody Fab fragment directed against the receptor) has been shown to diminish ischemic complications among patients undergoing high-risk coronary angioplasty ... Full text Link to item Cite

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Journal Article Lancet · May 17, 1997 BACKGROUND: Platelet-mediated thrombosis has been implicated in the development of ischaemic complications of percutaneous coronary intervention. We investigated whether inhibition of the platelet glycoprotein IIb/IIIa integrin with eptifibatide (Integrili ... Link to item Cite

The natural history of single-vessel chronic coronary occlusion: a 25-year experience.

Journal Article Am Heart J · April 1997 To determine the natural history of patients with a total occlusion of a single coronary artery, we searched the Duke Databank for Cardiovascular Disease to find all patients who underwent a first coronary angiogram >2 days after a symptomatic myocardial i ... Full text Link to item Cite

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

Journal Article Circulation · February 18, 1997 BACKGROUND: Platelets play a crucial role in the ischemic complications of percutaneous coronary procedures. The recent availability of c7E3 Fab (abciximab; ReoPro), a chimeric monoclonal antibody Fab fragment directed against the platelet glycoprotein IIb ... Full text Link to item Cite

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.

Journal Article Am J Cardiol · February 1, 1997 Blockade of the platelet glycoprotein IIb/IIIa receptor by abciximab (c7E3 Fab) during coronary intervention reduces the incidence of ischemic complications, but has been associated with a doubling of the risk for bleeding complications. The present pilot ... Full text Link to item Cite

Is there a differential benefit of ReoPro during PTCA for patients with certain lesion types?

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 1997 Link to item Cite

What predicts contrast nephropathy after coronary intervention? Insights from the IMPACT II trial

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 1997 Link to item Cite

Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art.

Journal Article J Thromb Thrombolysis · 1997 Platelets have been shown to play an important role in the pathogenesis of atherosclerosis, acute coronary syndromes, and ischemic complications after percutaneous coronary intervention. Fibrinogen binding via platelet surface glycoprotein (GP) IIb/IIIa re ... Full text Link to item Cite

Platelet and thrombin inhibitors as adjuncts to thrombolytic therapy and percutaneous coronary interventions: A review

Journal Article Journal of Interventional Cardiology · January 1, 1997 A large body of evidence supports the critical role of thrombus formation in the pathogenesis of acute MI as well as the early ischemic complications after percutaneous coronary interventions. Both platelets and the plasma proteins involved in fibrin forma ... Full text Cite

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.

Journal Article Am J Cardiol · August 14, 1996 Clinical evaluation of the antiplatelet glycoprotein (GP) IIb/IIIa receptor antagonists has now extended over nearly a decade. The largest experience to date with this new class of agents has been in the prevention and management of complications of percut ... Full text Link to item Cite

Saline infusion in excimer laser coronary angioplasty.

Journal Article Semin Interv Cardiol · June 1996 While the effects of high-intensity laser energy on tissue were studied early in the development of the laser, the interactions of laser radiation with immersion media have been the subject of more recent investigations. Prompted by reports of severe, morp ... Link to item Cite

Relation between activated clotting time during angioplasty and abrupt closure.

Journal Article Circulation · February 15, 1996 BACKGROUND: The purpose of this study was to determine whether the degree of heparin anticoagulation during coronary angioplasty, as measured by the activated clotting time, is related to the risk of abrupt vessel closure. METHODS AND RESULTS: Sixty-two ca ... Full text Link to item Cite

Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective

Journal Article American Journal of Cardiology · 1996 Clinical evaluation of the antiplatelet glycoprotein (GP) IIb/IIIa receptor antagonists has now extended over nearly a decade. The largest experience to date with this new class of agents has been in the prevention and management of complications of percut ... Cite

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

Journal Article Am J Cardiol · December 15, 1995 We studied the pharmacokinetic and pharmacodynamic properties of integrelin, a novel platelet glycoprotein IIb/IIIa receptor inhibitor, in patients undergoing elective percutaneous coronary intervention. Patients were randomized to placebo (n = 19) or to 1 ... Full text Link to item Cite

The changing profile of patient selection, procedural techniques, and outcomes in excimer laser coronary angioplasty. Participating Investigators of the Percutaneous Excimer Laser Coronary Angioplasty Registry.

Journal Article J Interv Cardiol · December 1995 During the course of development of excimer laser angioplasty, several changes in patient selection and technique have occurred. It is uncertain, however, whether these changes have been associated with improved procedural outcome. In this study, multivari ... Full text Link to item Cite

An overview of the results of the EPIC trial.

Journal Article Eur Heart J · November 1995 The Evaluation of 7E3 for the Prevention of Ischaemic Complications (EPIC) trial assessed the use of abciximab in the treatment of patients at high risk undergoing percutaneous revascularization procedures. Abciximab (c7E3) is a chimeric monoclonal antibod ... Full text Link to item Cite

Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.

Journal Article Eur Heart J · November 1995 Aggregation of platelets leading to thrombosis is one of the hallmarks of unstable angina, acute myocardial infarction, and ischaemic complications following coronary angioplasty. Activated platelets bind to fibrinogen through the glycoprotein IIb/IIIa int ... Full text Link to item Cite

Section review: Cardiovascular & renal: Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors

Journal Article Expert Opinion on Investigational Drugs · November 1, 1995 Platelets have been shown to play a significant role in the pathophysiology of acute coronary syndromes and the complications associated with percutaneous coronary intervention (abrupt closure and long-term restenosis). Recent efforts to inhibit platelets ... Full text Cite

Color Doppler sonographic appearance of patent needle tracts after femoral arterial catheterization.

Journal Article Radiology · October 1995 PURPOSE: To determine the color Doppler sonographic characteristics and clinical relevance of persistent needle tracts after femoral arterial puncture. MATERIALS AND METHODS: After diagnostic (n = 18,825) or interventional (n = 8,489) cardiac catheterizati ... Full text Link to item Cite

Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.

Journal Article Am Heart J · September 1995 Novel antithrombotic and antiplatelet agents may help reduce the short-term risk of ischemic complications and the long-term risk of restenosis in patients undergoing coronary revascularization procedures. Recent clinical trials suggest that, compared with ... Full text Link to item Cite

Ultrasonographically guided manual compression of femoral artery injuries.

Journal Article J Ultrasound Med · September 1995 To determine the success and complication rates of ultrasonographically guided manual compression in patients with femoral arterial injuries after femoral arterial catheterization, we performed 53 sonographically guided compression repairs in 51 patients. ... Full text Link to item Cite

Early and late quantitative angiographic results of vein graft lesions treated by excimer laser with adjunctive balloon angioplasty.

Journal Article Circulation · August 1, 1995 BACKGROUND: Percutaneous excimer laser coronary angioplasty (PELCA) has been approved for treatment of diseased saphenous vein bypass grafts. However, detailed and complete quantitative angiographic analysis of immediate procedural and late follow-up resul ... Full text Link to item Cite

Percutaneous revascularization of chronic coronary occlusions: an overview.

Journal Article J Am Coll Cardiol · July 1995 Patients with a chronic coronary occlusion often undergo coronary angiography after weeks to months of occlusion. The published reports underestimate the extent of this problem because such patients are often arbitrarily assigned to receive medical therapy ... Full text Link to item Cite

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.

Journal Article Circulation · April 15, 1995 BACKGROUND: Platelet aggregation and thrombosis have been implicated in the pathogenesis of coronary angioplasty complications. Integrelin, a synthetic cyclic heptapeptide with high affinity and marked specificity for platelet integrin glycoprotein IIb/III ... Full text Link to item Cite

Development of a new technique for reducing pressure pulse generation during 308-nm excimer laser coronary angioplasty.

Journal Article Cathet Cardiovasc Diagn · January 1995 Despite expectations that excimer laser ablation would result in a low incidence of coronary dissection, studies have documented a 15-20% incidence of dissection (including a 4-6% incidence of clinically significant dissection) during excimer interventions ... Full text Link to item Cite

Trials of interventional devices

Journal Article Journal of Myocardial Ischemia · January 1, 1995 Cite

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

Journal Article Circulation · October 1994 BACKGROUND: Thrombosis has been implicated as central to the clinical complications of coronary angioplasty (PTCA). Chimeric monoclonal 7E3 Fab (c7E3 Fab) is the first of a new class of antiplatelet drugs directed at the platelet glycoprotein IIb/IIIa inte ... Full text Link to item Cite

Predicting the risk of abrupt vessel closure after angioplasty in an individual patient.

Journal Article J Am Coll Cardiol · October 1994 OBJECTIVES: We proposed to examine the relation between angiographic morphologic characteristics and abrupt closure after coronary angioplasty and to develop an empirically based risk stratification system. BACKGROUND: Certain lesion morphologic characteri ... Full text Link to item Cite

HEPARIN DURING CORONARY ANGIOPLASTY - ARE THERE ANY RULES

Journal Article CIRCULATION · October 1, 1994 Link to item Cite

Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry.

Journal Article Am J Cardiol · July 15, 1994 A total of 495 patients underwent treatment with excimer laser angioplasty for 545 saphenous vein graft stenoses. Clinical success was achieved in 455 of 495 patients (92%), as indicated by < or = 50% residual stenosis at every target lesion and no complic ... Full text Link to item Cite

Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry.

Journal Article Circulation · July 1994 BACKGROUND: After direct angioplasty in the setting of acute myocardial infarction, patients were followed clinically and angiographically for 6 months at six experienced centers to evaluate outcomes. METHODS AND RESULTS: Of 258 patients with 6-month follo ... Full text Link to item Cite

Acute complications of excimer laser coronary angioplasty: a detailed analysis of multicenter results. Coinvestigators of the U.S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries.

Journal Article J Am Coll Cardiol · May 1994 OBJECTIVES: The aim of this study was to document and analyze the incidence and consequences of complications of excimer laser coronary angioplasty. BACKGROUND: Excimer laser coronary angioplasty has been reported to be a safe and feasible alternative or a ... Full text Link to item Cite

Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty.

Journal Article Circulation · May 1994 BACKGROUND: Survival after coronary artery bypass graft surgery (CABG) and medical therapy in patients with coronary artery disease (CAD) has been studied in both randomized trials and observational treatment comparisons. Over the past decade, the use of c ... Full text Link to item Cite

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.

Journal Article Lancet · April 9, 1994 Restenosis after coronary angioplasty occurs in at least 30% of patients in the first six months and, as yet, there is no known treatment to decrease this event. We tested a monoclonal antibody Fab fragment (c7E3) directed against the platelet glycoprotein ... Full text Link to item Cite

[Laser coronary angioplasty. Critical analysis of the first patients].

Journal Article Arq Bras Cardiol · April 1994 PURPOSE: To evaluate the success rate and complications, as well as the technical difficulties involved catheter laser coronary angioplasty, making evident the unsuccessful cases. METHODS: Twenty eight patients were treated with laser from August to Novemb ... Link to item Cite

Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry).

Journal Article Am J Cardiol · April 1, 1994 During a 14-month period, 6 experienced centers prospectively enrolled 271 patients into a registry in which percutaneous transluminal coronary angioplasty was the primary treatment for acute myocardial infarction. Patients age > 18 years who presented wit ... Full text Link to item Cite

IMMEDIATE, REVERSIBLE PLATELET-AGGREGATION INHIBITION IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · February 1, 1994 Link to item Cite

Dosing and administration of ReoPro (c7E3 Fab).

Journal Article J Invasive Cardiol · 1994 Link to item Cite

UNTITLED

Journal Article JOURNAL OF INVASIVE CARDIOLOGY · January 1, 1994 Link to item Cite

Laser coronary angioplasty. Critical analysis of the first patients

Journal Article Arquivos brasileiros de cardiologia · January 1, 1994 PURPOSE--To evaluate the success rate and complications, as well as the technical difficulties involved catheter laser coronary angioplasty, making evident the unsuccessful cases. METHODS--Twenty eight patients were treated with laser from August to Novemb ... Cite

Long-term outcome following successful reopening of abrupt closure after coronary angioplasty.

Journal Article Am J Cardiol · July 1, 1993 Abrupt closure after coronary angioplasty is often successfully treated by repeat dilation. Long-term follow-up, including 6-month repeat catheterization and 12-month clinical evaluation, was obtained in 1,056 patients treated with acute (n = 335) or elect ... Full text Link to item Cite

Treatment of long coronary artery narrowings with long angioplasty balloon catheters.

Journal Article Am J Cardiol · June 1, 1993 Balloon angioplasty of long coronary artery narrowings has been associated with a lower rate of acute success, and a higher rate of acute complications and restenosis than that observed for short narrowings. Angioplasty catheters with longer length balloon ... Full text Link to item Cite

Coronary artery perforation during excimer laser coronary angioplasty. The percutaneous Excimer Laser Coronary Angioplasty Registry.

Journal Article J Am Coll Cardiol · April 1993 OBJECTIVES: The aim of this study was to analyze the risk of vessel perforation during excimer laser angioplasty. BACKGROUND: Vessel perforation is a serious complication of angioplasty. METHODS: A total of 764 patients had 858 stenoses treated with excime ... Full text Link to item Cite

Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty.

Journal Article Coron Artery Dis · February 1993 BACKGROUND: Excessive platelet deposition at the site of arterial damage due to coronary angioplasty plays an important role in the pathophysiology of both abrupt closure and restenosis after that procedure. Even aspirin, a relatively weak platelet antagon ... Full text Link to item Cite

Does reperfusion improve prognosis when mitral regurgitation complicates infarction?

Journal Article Cardiology Board Review · January 1, 1993 Cite

Managing myocardial infarction complicated by mitral regurgitation

Journal Article Primary Cardiology · January 1, 1993 Acute ischemic mitral regurgitation associated with myocardial infarction can be diagnosed by Doppler echocardiography or cardiac catheterization with ventriculography. Hemodynamically stable patients should be managed medically, with afterload reduction; ... Cite

Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry.

Journal Article Am J Cardiol · December 15, 1992 The role of excimer laser angioplasty in treating complex coronary artery disease remains uncertain. A randomized trial comparing this new technology with balloon angioplasty cannot be designed until systematic analysis identifies the lesion types that are ... Full text Link to item Cite

Percutaneous excimer laser coronary angioplasty: development of technology and initial clinical results

Journal Article Proceedings of SPIE - The International Society for Optical Engineering · December 1, 1992 The development of laser systems suitable for vascular angioplasty is a multidisciplinary endeavor that includes development of the laser energy source, guidance modality, delivery catheter, and assessment of clinical applicability. In this paper we report ... Cite

Coronary angioplasty performed with gradual and prolonged inflation using a perfusion balloon catheter: procedural success and restenosis rate.

Journal Article Am Heart J · September 1992 The results of routine coronary angioplasty using gradual and prolonged balloon inflation with a perfusion balloon catheter were evaluated. One hundred forty patients were treated with inflation of the balloon to 6 atm over 3 minutes, with a median inflati ... Full text Link to item Cite

Prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans.

Journal Article J Am Coll Cardiol · September 1992 OBJECTIVES: The purpose of this study was to further explore the procedural safety of prolonged (15-min) dilation using an autoperfusion coronary angioplasty balloon by assessing the degree of myocardial damage or hemolysis, if any, occurring as a result o ... Full text Link to item Cite

Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction.

Journal Article Ann Intern Med · July 1, 1992 OBJECTIVE: To describe outcomes of patients sustaining an acute myocardial infarction complicated by mitral regurgitation managed with contemporary reperfusion therapies. DESIGN: Inception cohort case study. Long-term follow-up was obtained in 99% of all p ... Full text Link to item Cite

Outcome after prolonged balloon inflations of greater than 20 minutes for initially unsuccessful percutaneous transluminal coronary angioplasty.

Journal Article Am J Cardiol · June 1, 1992 Prolonged balloon inflation with or without autoperfusion techniques is a common initial approach to major dissection or abrupt occlusion after percutaneous transluminal coronary angioplasty (PTCA). To assess such a strategy in the setting of unsuccessful ... Full text Link to item Cite

Intracoronary ultrasound evaluation of interventional technologies.

Journal Article Am J Cardiol · November 15, 1991 The feasibility and applicability of intravascular ultrasound (IVUS) of the coronary arteries were evaluated in 65 patients undergoing 70 coronary interventional procedures. Morphologic and quantitative analyses were performed with a mechanically rotated I ... Full text Link to item Cite

Restenosis after coronary angioplasty: an overview.

Journal Article J Am Coll Cardiol · May 1991 Despite substantial basic and clinical efforts to address the problem of restenosis after percutaneous coronary intervention, effective preventive therapies have not yet been developed. Nevertheless, the accumulated information has provided much insight in ... Full text Link to item Cite

RESTENOSIS AFTER CORONARY ANGIOPLASTY - AN OVERVIEW

Journal Article JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · May 1, 1991 Link to item Cite

Quantitative analysis of cardiac images: Application in the clinical environment

Journal Article MedicaMundi · January 1, 1991 This article describes the application of quantitative cardiac analysis in a high volume clinical environment. Computerized evaluation is applied for measurement of coronary artery stenoses, and for determination of global and regional ventricular function ... Cite

EFFECTS OF UNSTABLE SYMPTOMS ON RESTENOSIS

Journal Article CIRCULATION · October 1, 1990 Link to item Cite

EFFECT OF ANGIOPEPTIN ON ATHEROGENESIS IN CYNOMOLGOUS MACAQUES

Journal Article ARTERIOSCLEROSIS · September 1, 1990 Link to item Cite

INTERVENTIONAL CARDIAC-CATHETERIZATION AT DUKE-MEDICAL-CENTER

Journal Article AMERICAN JOURNAL OF CARDIOLOGY · October 1, 1988 Link to item Cite

Interventional Cardiac Catheterization at Duke Medical Center - The Duke Interventional Cardiac Catheterization Program

Journal Article American Journal of Cardiology · January 1, 1988 Clinical perspective: Cardiac revascularization in a wide range of patients with coronary artery disease is the underlying mission of Duke University's Interventional Cardiac Catheterization Program, one of the largest of its kind in the United States. Und ... Cite

New international technology: The autoperfusion balloon catheter

Journal Article American Journal of Cardiology · January 1, 1988 Clinical perspective: Balloon angioplasty reduces mortality and morbidity in AMI and coronary artery disease patients, but the procedure has major limitations. Acute failure requiring an emergency response is not uncommon, and the restenosis rate is greate ... Cite

Limitations of balloon angioplasty: Possible causes of restenosis

Journal Article American Journal of Cardiology · January 1, 1988 Clinical perspective: Much needs to be learned about the precise physiologic and biochemical actions and effects of thrombolytic therapy and PTCA in various settings. In particular, the factors influencing restenosis must be elucidated. ... Cite

Balloon angioplasty in acute myocardial infarction - Limitations of thrombolytic therapy when used alone

Journal Article American Journal of Cardiology · 1988 Clinical perspective: Although thrombolytic therapy offers important, often life-preserving benefits to many AMI patients, its effectiveness is limited in several crucial respects: it does not achieve reperfusion in a substantial percentage of patients, no ... Cite

Purification and properties of DNA polymerase-beta from guinea pig liver.

Journal Article Biochim Biophys Acta · September 27, 1978 Deoxyribonucleic acid polymerase-beta (EC 2.7.7.7) has been purified over 100 000-fold from a whole cell extract of guinea pig liver. The enzyme yields a single stainable band when subjected to non-denaturing polyacrylamide gel electrophoresis, and this ba ... Full text Link to item Cite

Novikoff hepatoma deoxyribonucleic acid polymerase. Sensitivity of the beta-polymerase to sulfhydryl blocking agents.

Journal Article Nucleic Acids Res · September 1976 Unlike other beta-class eukaryotic DNA polymerases, the enzyme purified from the Novikoff hepatoma is inhibited by both sulfhydryl blocking agents N-ethylmaleimide (NEM) and p-hydroxymercuribenzoate (pHMB). The degree of sensitivity varies depending on the ... Full text Link to item Cite